Related Experiment Videos
Metrizamide--CSF contrast medium. Analysis of clinical application in 215 patients
Radiology
|June 1, 1977
Summary
Metrizamide, a new water-soluble contrast agent, was evaluated in 215 patients. While 67% experienced side effects, its benefits in subarachnoid imaging outweigh the risks.
Area of Science:
- Radiology
- Neurology
- Medical Imaging
Background:
- The subarachnoid space requires precise contrast agent delivery for diagnostic imaging.
- Water-soluble contrast agents offer potential advantages for neuroradiological procedures.
Purpose of the Study:
- To evaluate the safety and efficacy of metrizamide, a novel water-soluble contrast agent.
- To assess the incidence and severity of side effects associated with metrizamide administration.
Main Methods:
- A cohort of 215 patients received metrizamide for subarachnoid space imaging.
- Cervical injections were utilized, with fluoroscopic monitoring for precise contrast medium positioning.
Main Results:
- Metrizamide was administered to 215 patients for subarachnoid imaging.
- Overall, 67% of patients reported side effects.
- Moderate to severe side effects occurred in 39% of patients.
Conclusions:
- Metrizamide is a usable water-soluble contrast agent for subarachnoid imaging.
- Despite a high rate of side effects, the benefits of metrizamide are considered to outweigh its risks in this patient cohort.